Whether AstraZeneca PLC will be able to differentiate the lead molecules in its overhauled oncology pipeline will be the test of the company’s efforts to rebuild its franchise and turn oncology into a growth engine.
The oncology franchise is a spotlight for the company and pivotal to the turn-around plan outlined by CEO Pascal Soriot...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?